CCNE1 Is a Novel Synthetic Lethal Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma

被引：0
|
作者：
Kawahara, Naoki [1 ]
Yamada, Yuki [1 ]
Kawaguchi, Ryuji [1 ]
机构：
[1] Nara Med Univ, Dept Obstet & Gynecol, Nara, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3026
引用
收藏
页码：1845 / 1845
页数：1
相关论文
共 50 条
  • [11] CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis
    Ayhan, Ayse
    Kuhn, Elisabetta
    Wu, Ren-Chin
    Ogawa, Hiroshi
    Bahadirli-Talbott, Ash
    Mao, Tsui-Lien
    Sugimura, Haruhiko
    Shih, Ie-Ming
    Wang, Tian-Li
    MODERN PATHOLOGY, 2017, 30 (02) : 297 - 303
  • [12] Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma
    Oaknin, A.
    Drescher, C.
    Banda, K.
    Duska, L.
    Ribrag, V.
    Tewari, A.
    Lakhani, N. J.
    Eberst, L.
    Harvey, R. D.
    Sanchez, L. M. Manso
    Lorusso, D.
    Kindler, H.
    Walter, H. S.
    Illescas, D. G.
    Pons-Tostivint, E.
    Thakur, A. G.
    Kann, L.
    Reddy, A.
    Faulhaber, N.
    Gonzalez-Martin, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S567 - S568
  • [13] Therapeutic approaches for ARID1A-mutated ovarian cancer.
    Zhang, Rugang
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 26 - 26
  • [14] Synthetic lethal interaction between ARID1A mutation and BET bromodomain inhibition in ovarian clear cell carcinoma
    Berns, Katrien
    Caumanns, Joseph J.
    Hijmans, E. Marielle
    Gennissen, Annemiek
    Evers, Bastiaan
    Wisman, Bea A.
    Meersema, Gert Jan
    Lieftink, Cor
    Beijersbergen, Roderick L.
    Itamochi, Hiroaki
    van der Zee, Ate G.
    de Jong, Steven
    Bernards, Rene
    CANCER RESEARCH, 2017, 77
  • [15] Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
    Miller, Rowan E.
    Brough, Rachel
    Bajrami, Ilirjana
    Williamson, Chris T.
    McDade, Simon
    Campbell, James
    Kigozi, Asha
    Rafiq, Rumana
    Pemberton, Helen
    Natrajan, Rachel
    Joel, Josephine
    Astley, Holly
    Mahoney, Claire
    Moore, Jonathan D.
    Torrance, Chris
    Gordan, John D.
    Webber, James T.
    Levin, Rebecca S.
    Shokat, Kevan M.
    Bandyopadhyay, Sourav
    Lord, Christopher J.
    Ashworth, Alan
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (07) : 1472 - 1484
  • [16] ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma
    Sato, Emi
    Nakayama, Kentaro
    Razia, Sultana
    Nakamura, Kohei
    Ishikawa, Masako
    Minamoto, Toshiko
    Ishibashi, Tomoka
    Yamashita, Hitomi
    Iida, Kouji
    Kyo, Satoru
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (06):
  • [17] Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
    Fukumoto, Takeshi
    Park, Pyoung Hwa
    Wu, Shuai
    Fatkhutdinov, Nail
    Karakashev, Sergey
    Nacarelli, Timothy
    Kossenkov, Andrew V.
    Speicher, David W.
    Jean, Stephanie
    Zhang, Lin
    Wang, Tian-Li
    Shih, Ie-Ming
    Conejo-Garcia, Jose R.
    Bitler, Benjamin G.
    Zhang, Rugang
    CELL REPORTS, 2018, 22 (13): : 3393 - 3400
  • [18] CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma
    Mei, Jie
    Tian, Huixiang
    Huang, Hsuan-Shun
    Wu, Nayiyuan
    Liou, Yu-Ligh
    Chu, Tang-Yuan
    Wang, Jing
    Zhang, Wei
    CELL CYCLE, 2023, 22 (01) : 85 - 99
  • [19] ARID1A-mutated ovarian cancers depend on HDAC6 activity
    Benjamin G. Bitler
    Shuai Wu
    Pyoung Hwa Park
    Yang Hai
    Katherine M. Aird
    Yemin Wang
    Yali Zhai
    Andrew V. Kossenkov
    Ana Vara-Ailor
    Frank J. Rauscher III
    Weiping Zou
    David W. Speicher
    David G. Huntsman
    Jose R. Conejo-Garcia
    Kathleen R. Cho
    David W. Christianson
    Rugang Zhang
    Nature Cell Biology, 2017, 19 : 962 - 973
  • [20] A key HDAC6 dependency of ARID1A-mutated ovarian cancer
    Altucci, Lucia
    NATURE CELL BIOLOGY, 2017, 19 (08) : 889 - 890
12345